预约演示

After GSK acquisition, Bellus CEO seeks work opportunities for displaced staff

2024-03-22

并购临床2期临床3期

On LinkedIn, former CEO Roberto Bellini wrote that most Bellus employees will wrap up their work with the company after last summer's GSK acquisition.

After GSK’s $2 billion buyout of Canada-based Bellus HeaBellusst summer, an undisclosed number of the biotech’s team members are out oGSK job.

“When GSK companies come together during an acBellus Healthe capabilities across both companies are evaluated to determine the best path forward for the acquired portfolio,” a GSK spokesperson told Fierce Biotech in an emailed statement March 22. “During the GSK Bellus acquisition, we retained employees to a predetermined date to ensure the successful integration of the business. As often is the case during this process, redundancies may occur.”

While it’s unclear how many Bellus staff members will lose their jobs, former Bellus CEO Roberto Bellini wrote, “After having completed the transition activities linked to the GSK acquisition, most Bellus Health employees will be wrapping up their involvementGSKth the company on March 31,” in a March 21 LinkedIn post.

The former CEO went on to voBellusr his former staff members, tagging more thaBelluseople looking for new work opportunities.GSK Bellus Health

The acquisition closed in June 2023 and centered around a P2X3 antagonist called camlipixant, a molecule with the same mechanism of action as Merck & Co.’s unapproved chronic cough med gefapixant.

Bellus took camlipixant into a pair of late-phase chronic P2X3 antagonistutting icamlipixantto deliver data in the second half of this year anMerck & Co., GSK has pockchronic coughe 3 dgefapixantpects to win approval for camlipixant with a launch in 2026.

The British camlipixantpaid out $14.75 per Bellus chronic cough premium over the biotech’s most recent closing price at the time. The payment marks a signiGSKant turnaround from just a few years prior when Bellus traded bcamlipixanter a 2020 mid-phase trial flop for camlipixant. Following that trial failure, the biotech managed to recover its share price with the release of phase 2b data late in 2021.

Now,Britishll keep driving phase 3 camlipixBellusvelopment forward to address an unmet need among patients with refractory chronic cough, the company spokesperson said.Bellus camlipixant

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构